Last updated: 2026-09-07 17:16:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
CytoMed Therapeutics Limited (GDTC) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0.88, with a market capitalization of $10.19M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.68 to $3.68. This page covers its latest market performance, valuation, price trends and company information.
$10.19M | |
$0.93 | |
$9.25 | |
$0.68 | |
-- | |
16.51K | |
80.37K | |
-- | |
$3.68 | |
$0.68 | |
-- | |
-- |
CytoMed Therapeutics Limited (GDTC) last closed at $0.00 as of 2026-09-04 22:05:00, -- from the previous close of $0.00.
During the latest regular trading session, GDTC traded between $0.68 and $9.25, with a volume of 16.51K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, CytoMed Therapeutics Limited (GDTC) moved from $0.94 to $0.88, representing a decline of 6.42% ($0.06).
The stock traded between $0.76 and $1.00 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 13.43 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 6.5%
GDTC is currently trading at $0.88, placing it 6.5% of the way from its 52-week low of $0.68 to its 52-week high of $3.68. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
| Employees | 42 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CytoMed Therapeutics Limited (GDTC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.